NCT07575399
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Recruiting
PHASE3Ages 18–99InterventionalTreatmentAmgen
~300 participants
Updated 2026-07-23 on ClinicalTrials.gov
What's tested:Maridebart Cafraglutide
At a glance
Recruiting sites
44 of 44 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent Change from Baseline in Body Weight at Week 68
Measured over Week 68
Conditions
Where it's being run
44 sites across 18 statesFlorida9
Texas8
California5
Georgia3
North Carolina3
Arizona2
New York2
Oklahoma2
Study leadership
- MD · STUDY_DIRECTOR · Amgen
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Body Mass Index (BMI) ≥ 25 at screening.
Weight loss of ≥ 10% on weekly GLP-1 RA.
Stable body weight.
Stable dose of GLP-1RA.
Stable gastrointestinal (GI) tolerability.
Contraception for females.
Willingness to follow trial procedures for the duration of the trial.
Exclusion
Obesity induced by other endocrine disorders (ex: Cushing's syndrome).
Previous or planned surgical, endoscopic or device-based treatment for obesity.
History of malignancy.
Type 1/Type 2 diabetes mellitus (DM).
Family or personal history of medullary thyroid cancer.
Previous participation in a Maridebart Cafraglutide trial.
What this trial measures
- Percent Change from Baseline in Body Weight at Week 68Week 68